The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISAL 2023 | Using AI to segment and classify bone marrow cells in patients with AML
Philippe Leleux, PhD, Toulouse University Hospital, Toulouse, France, discusses a study that used artificial intelligence (AI) to segment and classify bone marrow cells with multi-precision numeration of bone marrow smears from patients with acute myeloid leukemia (AML), outlining the techniques used in this study. Dr Leleux explains that this method enabled automated analysis of bone marrow smears, blast quantification, and accurate identification of different cell lines, which will ultimately aid the diagnosis of AML. Dr Leleux also emphasizes the increasing importance of AI to exploit the vast amounts of data generated from studies. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
